Recursion Pharmaceuticals, Inc. RXRX Enterprise value

Enterprise value at other companies

SchrodingerSDGR

$1.03B-26.2%

Absci CorporationABSI

$453.38M+73.1%

AbCellera Biologics Inc.ABCL

$2.39B+113%

Relay Therapeutics, Inc.RLAY

$3.99B+717%

Septerna, Inc.SEPN

$1.03B+1,325%

XencorXNCR

$1.32B+74.2%

FAQ

What is Recursion Pharmaceuticals, Inc.'s enterprise value?

Recursion Pharmaceuticals, Inc. (RXRX) reported enterprise value of $1.47B in Q2 2026.

How has Recursion Pharmaceuticals, Inc.'s enterprise value changed year-over-year?

Recursion Pharmaceuticals, Inc.'s enterprise value decreased by 13.4% year-over-year, from $1.7B to $1.47B.

What is the long-term trend for Recursion Pharmaceuticals, Inc.'s enterprise value?

Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s enterprise value has grown at a -13.9% compound annual growth rate (CAGR), from $2.68B to $1.47B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.